Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bronchopulmory Dysplasia - Overview
Bronchopulmory Dysplasia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Bronchopulmory Dysplasia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bronchopulmory Dysplasia - Companies Involved in Therapeutics Development
Advent Therapeutics Inc
Airway Therapeutics LLC
APIE Therapeutics Inc
Ayuvis Research Inc
Boehringer Ingelheim Intertiol GmbH
Chiesi Farmaceutici SpA
Insmed Inc
MediPost Co Ltd
Meridigen Biotech Co Ltd
Orphanix GmbH
Radikal Therapeutics Inc
Syntrix Biosystems Inc
Takeda Pharmaceutical Co Ltd
The Cell Factory BVBA
Trimunocor Ltd
Velvio GmbH
Bronchopulmory Dysplasia - Drug Profiles
APT-D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVR-48 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CFMEV-132 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Bronchopulmory Dysplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mecasermin rinfabate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Inhibit FLT1 for Bronchopulmory Dysplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVP-13 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVP-19 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
perfluorooctyl bromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pioglitazone + B-YL - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pneumostem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-908 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint Surfactant Associated Protein D Replacement for Bronchopulmory Dysplasia and Lung Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SX-576 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tiotropium bromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UMC-11901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vitamin A palmitate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vitamin A palmitate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bronchopulmory Dysplasia - Dormant Projects
Bronchopulmory Dysplasia - Discontinued Products
Bronchopulmory Dysplasia - Product Development Milestones
Featured News & Press Releases
Mar 26, 2021: Airway Therapeutics announces FDA acceptance of IND for AT-100 in preterm infants at risk for bronchopulmory dysplasia (BPD)
Aug 23, 2019: Medipost’s Pneumostem gets FDA’s fast-track desigtion
May 15, 2019: Meridigen new Neotal Stem Cell Drug received TFDA Approval for Clinical Trial
Feb 27, 2019: Esperite N.V. with The Cell Factory has confirmed a long-term effect of extracellular vesicle drug candidate CF-MEV-132 for the treatment of bronchopulmory dysplasia.
Nov 06, 2018: Esperite Group with The Cell Factory expands its extracellular vesicles product portfolio of anti-inflammatory drugs with a fourth indication : Bronchopulmory Dysplasia
Aug 24, 2018: Airway Therapeutics announces appointment of chief medical officer
May 03, 2016: MEDIPOST receives US Patent for ?PNEUMOSTEM’ for Treating Lung Disease
Sep 14, 2014: MediPost America clears Phase 1/2 IND for the U.S. clinical trial on stem cell drug for lung
Aug 12, 2014: MediPost, lung disease stem cell treatment drug ’Pneumostem’ application for US clinical trial
Jul 29, 2014: Lung disease stem cell drug desigted ?orphan drug in development stage’
Feb 06, 2014: Stem cells to treat lung disease in preterm infants
Sep 26, 2012: Medipost Receives KFDA Approval For Phase II Clinical Trial Of Lung Disease Medicine Pneumostem
May 31, 2012: Medipost Submits Application To KFDA For Pneumostem Clinical Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Bronchopulmonary Dysplasia, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Bronchopulmonary Dysplasia, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Bronchopulmonary Dysplasia - Pipeline by Advent Therapeutics Inc, 2021
Bronchopulmonary Dysplasia - Pipeline by Airway Therapeutics LLC, 2021
Bronchopulmonary Dysplasia - Pipeline by APIE Therapeutics Inc, 2021
Bronchopulmonary Dysplasia - Pipeline by Ayuvis Research Inc, 2021
Bronchopulmonary Dysplasia - Pipeline by Boehringer Ingelheim International GmbH, 2021
Bronchopulmonary Dysplasia - Pipeline by Chiesi Farmaceutici SpA, 2021
Bronchopulmonary Dysplasia - Pipeline by Insmed Inc, 2021
Bronchopulmonary Dysplasia - Pipeline by MediPost Co Ltd, 2021
Bronchopulmonary Dysplasia - Pipeline by Meridigen Biotech Co Ltd, 2021
Bronchopulmonary Dysplasia - Pipeline by Orphanix GmbH, 2021
Bronchopulmonary Dysplasia - Pipeline by Radikal Therapeutics Inc, 2021
Bronchopulmonary Dysplasia - Pipeline by Syntrix Biosystems Inc, 2021
Bronchopulmonary Dysplasia - Pipeline by Takeda Pharmaceutical Co Ltd, 2021
Bronchopulmonary Dysplasia - Pipeline by The Cell Factory BVBA, 2021
Bronchopulmonary Dysplasia - Pipeline by Trimunocor Ltd, 2021
Bronchopulmonary Dysplasia - Pipeline by Velvio GmbH, 2021
Bronchopulmonary Dysplasia - Dormant Projects, 2021
Bronchopulmonary Dysplasia - Discontinued Products, 2021